Michael Amoroso
Known title: President and CEOCIK: 0001830874
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Abeona Reports ZEVASKYN Launch Momentum and Revenue Growth. Abeona Therapeutics highlighted positive momentum for its ZEVASKYN product launch and revenue growth during a recent H.C. Wainwright event. The company is also expanding its distribution network as the treatment for RDEB gains traction. These developments provide fundamental context for the stock, which is currently trading near its 52-week low.
Transaction History
| DTIL | ▼ Sell | Open Market | 20,559 | $79K | 2/18/2026 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 67,797 | $0 | 2/17/2026 | View on chart |
| ABEO | ▲ Buy | Grant | 37,313 | $0 | 1/26/2026 | View on chart |
| DTIL | ▼ Sell | Open Market | 34,799 | $145K | 1/22/2026 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 8,888 | — | 1/20/2026 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 37,069 | — | 1/20/2026 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 69,421 | — | 1/20/2026 | View on chart |
| DTIL | ▼ Sell | Open Market | 3,409 | $22K | 11/3/2025 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 9,444 | $0 | 11/2/2025 | View on chart |
| DTIL | ▼ Sell | Open Market | 964 | $5K | 3/24/2025 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 3,417 | — | 3/21/2025 | View on chart |
| ABEO | ▲ Buy | Grant | 36,101 | $0 | 1/31/2025 | View on chart |
| DTIL | ▼ Sell | Open Market | 36,838 | $172K | 1/21/2025 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 115,388 | — | 1/20/2025 | View on chart |
| DTIL | ▼ Sell | Open Market | 3,012 | $25K | 11/4/2024 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 9,443 | — | 11/2/2024 | View on chart |
| ABEO | ▲ Buy | Grant | 11,797 | $0 | 8/26/2024 | View on chart |
| ABEO | ▲ Buy | Grant | 23,611 | $0 | 7/8/2024 | View on chart |
| DTIL | ▲ Buy | Grant | 8,334 | $100K | 5/8/2024 | View on chart |
| DTIL | ▼ Sell | Open Market | 1,526 | $16K | 5/2/2024 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 3,417 | — | 5/1/2024 | View on chart |
| DTIL | ▼ Sell | Open Market | 137,390 | $49K | 1/22/2024 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 266,720 | — | 1/20/2024 | View on chart |
| DTIL | ▼ Sell | Open Market | 125,025 | $50K | 11/3/2023 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 283,390 | — | 11/2/2023 | View on chart |
| ABEO | ▼ Sell | Open Market | 5,508 | $22K | 9/27/2023 | View on chart |
| ABEO | ▼ Sell | Open Market | 327 | $1K | 9/20/2023 | View on chart |
| ABEO | ▼ Sell | Open Market | 338 | $2K | 6/20/2023 | View on chart |
| ABEO | ▲ Buy | Grant | 58,689 | $271K | 6/14/2023 | View on chart |
| DTIL | ▼ Sell | Open Market | 46,999 | $39K | 3/22/2023 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 102,535 | — | 3/21/2023 | View on chart |
| ABEO | ▼ Sell | Open Market | 268 | $624 | 3/20/2023 | View on chart |
| ABEO | ▼ Sell | Open Market | 1,002 | $2K | 3/3/2023 | View on chart |
| DTIL | ▼ Sell | Open Market | 11,006 | $15K | 10/17/2022 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 24,208 | — | 10/15/2022 | View on chart |
| ABEO | ▲ Buy | Grant | 13,400 | $0 | 9/26/2022 | View on chart |
| ABEO | ▼ Sell | Open Market | 45,409 | $49K | 9/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Precision BioSciences to Present HBV Data at AASLD 2026
Precision BioSciences announced a late-breaking oral presentation for its PBGENE-HBV candidate at the upcoming AASLD The Liver Meeting 2026. This event provides a scheduled future date for the company to share new clinical data, which is a key catalyst for stakeholders tracking the drug's development. The announcement highlights the company's ongoing focus on its hepatitis B virus program.
Precision BioSciences to Present HBV Data at AASLD 2026. Precision BioSciences announced a late-breaking oral presentation for its PBGENE-HBV candidate at the upcoming AASLD The Liver Meeting 2026. This event provides a scheduled future date for the company to share new clinical data, which is a key catalyst for stakeholders tracking the drug's development. The announcement highlights the company's ongoing focus on its hepatitis B virus program.